Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG82ZA)

• Drug Name: Ad35-GRIN/ENV Drug Info
• Synonyms: Ad35 vector-delivered gag/rt/int/nef + Ad35 vector-delivered env combination vaccine (HIV infection), International AIDS Vaccine Initiative

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMG82ZA

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus Rev protein (HIV rev)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATI-0917	DMT5Z84	Human immunodeficiency virus infection	1C62	Phase 1	[3]

Drug(s) Targeting Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TBC-M4	DM9CDPO	Human immunodeficiency virus infection	1C62	Phase 1	[4]
MGD014	DMZN5QX	Human immunodeficiency virus-1 infection	1C62	Phase 1	[5]
PENNVAX-6	DM0BNLC	Human immunodeficiency virus infection	1C62	Phase 1	[6]
Ad5-ENVA-48	DMMBQV3	Human immunodeficiency virus-1 infection	1C62	Phase 1	[7]
GPG	DMYR7LO	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1/2	[8]

Drug(s) Targeting Human immunodeficiency virus Reverse transcriptase (HIV RT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[9]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[10]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[11]
Tenofovir	DM1IS6U	Human immunodeficiency virus infection	1C62	Approved	[9]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[12]
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[13]
Delavirdine	DM3NF5G	Human immunodeficiency virus infection	1C62	Approved	[12]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[12]
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[14]
Etravirine	DMGV8QU	Human immunodeficiency virus-1 infection	1C62	Approved	[15]

Drug(s) Targeting Human immunodeficiency virus Negative factor (HIV nef)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
F4co vaccine	DM6UQNW	Human immunodeficiency virus infection	1C62	Phase 2	[16]
LIPO-5	DMWY0V1	Human immunodeficiency virus infection	1C62	Phase 2	[17]
Ad35-GRIN	DM4L28K	Human immunodeficiency virus infection	1C62	Phase 1/2	[2]
GSK-732461	DMJ0ZB6	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[18]
MYRISTIC ACID	DMYX0BL	Discovery agent	N.A.	Investigative	[19]

Drug(s) Targeting Human immunodeficiency virus GAG protein (HIV gag)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bevirimat	DML2D8Q	Human immunodeficiency virus infection	1C62	Phase 2	[20]
LIPO-5	DMWY0V1	Human immunodeficiency virus infection	1C62	Phase 2	[17]
Ad35-GRIN	DM4L28K	Human immunodeficiency virus infection	1C62	Phase 1/2	[2]
TBC-M4	DM9CDPO	Human immunodeficiency virus infection	1C62	Phase 1	[4]
RVSVIN HIV-1 gag vaccine	DMYRPC8	Human immunodeficiency virus infection	1C62	Phase 1	[21]
GSK-732461	DMJ0ZB6	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[18]
PA-1050040	DMF4KPM	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[22]
Gem 92	DM4ZDVY	Human immunodeficiency virus-1 infection	1C62	Discontinued in Phase 1	[23]
MPC-9055	DMCMNKV	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[24]
MPI-461359	DMAVD4Q	Human immunodeficiency virus infection	1C62	Terminated	[25]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)	TTEC2T3	ENV_HV1H2	Not Available	[2]
Human immunodeficiency virus GAG protein (HIV gag)	TTFGZB6	GAG_HV1H2	Not Available	[2]
Human immunodeficiency virus Negative factor (HIV nef)	TT4NXYM	NEF_HV1A2	Not Available	[2]
Human immunodeficiency virus Rev protein (HIV rev)	TTF7I5O	REV_HV1H2	Not Available	[2]
Human immunodeficiency virus Reverse transcriptase (HIV RT)	TT84ETX	POL_HV1B1	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT01496989) Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers. U.S. National Institutes of Health.
• [2] A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
• [3] Antiretroviral drugs in development. A report from HIV DART 2008: Frontiers in Drug Development for Antiretroviral Therapies, 9-12 December 2008, Rio Grande, Puerto Rico. Expert Opin Investig Drugs. 2009 Apr;18(4):549-53.
• [4] A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
• [5] Clinical pipeline report, company report or official report of MacroGenics.
• [6] Company report (Inovio)
• [7] ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health.
• [8] GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway. Retrovirology 2010, 7:20.
• [9] Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
• [10] HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
• [11] A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
• [14] Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
• [15] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [16] EP patent application no. 2621528, Vaccine.
• [17] HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
• [18] Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013.
• [19] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [20] Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem. 2013 Apr;62:453-65.
• [21] Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81.
• [22] US patent application no. 2015,0105,350, Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections.
• [23] Technology evaluation: GEM-92, Hybridon Inc. Curr Opin Mol Ther. 1999 Aug;1(4):521-3.
• [24] New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation . Antimicrob Agents Chemother. 2009 December; 53(12): 5080-5087.
• [25] Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology. 2012 Aug 6;9:63.